Skip to main content

Table 3 Cost consequence analysis

From: Cost effectiveness of intermittent screening followed by treatment versus intermittent preventive treatment during pregnancy in West Africa: analysis and modelling of results from a non-inferiority trial

 

IPTp-SP

ISTp-AL

Costs per 1000 pregnant women

Health provider excluding consequencesb (US$ 2012)

1631.84 (1100.11–2316.97)

5778.77 (4701.65–7039.15)a

Health provider including consequencesb (US$ 2012)

9006.54 (5610.30–13,680.56)

13,972.79 (10,199.65–18,983.86)a

Measurable outcomes contributing to DALYs per 1000 women [20]

LBW

151 (137–167)

156 (141–172)

severe/moderate anaemia

17 (12–25)

23 (17–32)

clinical malaria (total episodes)c

74 (61–92)

115 (96–144)

Other measurable outcomes per 1000 women and side effects [20, 37]

Placental malaria: active infection (acute and chronic)

245 (224–265)

242 (222–262)

Dizziness

46 (38–54)

25 (19–31)

Sleeplessness

13 (9–17)

7 (4–10)

Weakness

30 (24–37)

18 (13–23)

Nausea

22 (16–28)

13 (9–17)

Vomiting

45 (37–53)

26 (20–32)

Non measurable outcomes

Intrinsic value of giving less drugs to pregnant women

Value to individual of knowing about positive test

Value of knowing about positive test for surveillance

Deprivation of treatment for false negatives

  1. DALY disability adjusted life years; IPTp-SP intermittent preventive treatment with sulfadoxine-pyrimethamine; ISTp-AL intermittent screening followed by treatment with artemether-lumefantrine; LBW low birth weight
  2. aAt 24.7 % of administration where RDT showed a positive result
  3. bCosts from consequences = ∑ short term costs LBW baby; costs mod/sev anaemia episode; costs MiP episode
  4. cClinical malaria defined as illness + positive slide at an unscheduled visit